Thursday, May 25, 2023 3:28:29 PM
up up and away and they have to buy no matter the price
Recent OCEA News
- Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses • GlobeNewswire Inc. • 10/01/2024 12:01:00 PM
- Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms • GlobeNewswire Inc. • 08/27/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 08:30:33 PM
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 08/23/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 09:26:10 PM
- Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 • GlobeNewswire Inc. • 06/05/2024 11:01:00 AM
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 05/30/2024 11:44:00 AM
- Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease • GlobeNewswire Inc. • 05/16/2024 12:01:00 PM
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K • GlobeNewswire Inc. • 04/24/2024 08:51:06 PM
- Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL • GlobeNewswire Inc. • 03/28/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 10:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 10:22:43 PM
- Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting • GlobeNewswire Inc. • 02/29/2024 01:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 11:43:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 10:05:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:05:30 PM
- Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody • GlobeNewswire Inc. • 12/05/2023 01:15:00 PM
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 11/29/2023 10:41:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 11:20:11 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 11:20:04 AM
- Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics • GlobeNewswire Inc. • 11/14/2023 01:01:00 PM
- Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection • GlobeNewswire Inc. • 10/26/2023 09:30:00 AM
- Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infection • PR Newswire (US) • 10/26/2023 09:30:00 AM
- Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis • GlobeNewswire Inc. • 10/24/2023 10:30:00 AM
- Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics • GlobeNewswire Inc. • 10/17/2023 12:01:00 PM
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM